title: Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent.
abstract: Mebendazole, a well-known anti-helminthic drug in wide clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical studies across a number of different cancer types. Significantly, there are also two case reports of anti-cancer activity in humans. The data are summarised and discussed in relation to suggested mechanisms of action. Based on the evidence presented, it is proposed that mebendazole would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of mebendazole as an anti-cancer therapeutic is warranted. A number of possible combinations with other drugs are discussed in the Appendix.
authors: Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium ; The George Pantziarka TP53 Trust, London KT1 2JP, UK.
authors: Pan
authors: P
authors: Pantziarka
authors: Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.
authors: Gauthier
authors: G
authors: Bouche
authors: Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.
authors: Lydie
authors: L
authors: Meheus
authors: GlobalCures, Inc, Newton, MA 02459, USA.
authors: Vidula
authors: V
authors: Sukhatme
authors: GlobalCures, Inc, Newton, MA 02459, USA ; Beth Israel Deaconess Medical Centre and Harvard Medical School, Boston, MA 02215, USA.
authors: Vikas P
authors: VP
authors: Sukhatme
keywords: ReDO Project; anti-helminthic; cancer; drug repurposing; metronomic chemotherapy